Fedotozine

Fedotozine (INN; JO 1196 for the (-) tartrate salt) is an opioid drug of the arylacetamide series which acts as a peripherally specific selective κ1-opioid receptor agonist with preference for the κ1A subtype.[1][2] It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials,[1][3][4] but ultimately development was discontinued and it was never marketed.

Fedotozine
Clinical data
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H31NO4
Molar mass373.486 g/mol g·mol−1
3D model (JSmol)

See also

References
  1. Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs. 10 (1): 97–110. doi:10.1517/13543784.10.1.97. PMID 11116283.
  2. axonmedchem entry
  3. Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. doi:10.1517/13543784.6.10.1351. PMID 15989506.
  4. Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases. 24 (1–2): 91–8. doi:10.1159/000090312. PMID 16699267.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.